Palivizumab vs motavizumab
Total RSV hospital days per 100 children · patients at high risk of severe respiratory syncytial virus infection
1 finding from 1 review
- Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 7870 participantsLow